ZURA nears pivotal-trial readouts for IL-17/BAFF bispecific in autoimmunity
ZURA says upcoming pivotal-trial data in hidradenitis suppurativa and systemic sclerosis will test a bispecific antibody targeting IL-17 and BAFF, aiming to address efficacy ceilings in autoimmune diseases.